Literature DB >> 19169153

Progenitor cells in infantile hemangioma.

Joyce Bischoff1.   

Abstract

Infantile hemangioma is a vascular tumor that occurs in 5% to 10% of infants of European descent. A hallmark of infantile hemangioma is its life cycle, which is divided into 3 stages. The proliferating phase spans in the first year of postnatal life and is characterized by cellular masses without a defined vascular architecture and nascent blood vessels with red blood cells evident within the lumenal space. The involuting phase begins at 1 year of age and continues for 3 to 5 years. Proliferation slows or stops in this phase, and histologic examination shows that the blood vessel architecture becomes more obvious and vessel size is enlarged. The involuted phase reaches 5 to 8 years of age, at which point blood vessels are replaced with a fibrofatty residuum and capillary-sized channels. The growth and involution life cycle of infantile hemangioma are very different from other vascular tumors and vascular malformations, which do not regress and can occur at any time during childhood or adult life. Many laboratories have reported on the endothelial characteristics of the cellular masses that are prominent in the proliferating phase of infantile hemangioma, as well as their immature appearance. These studies, along with isolation and characterization of hemangioma-derived cell populations with progenitor cell properties, have lead to an emerging hypothesis that hemangioma is caused by an abnormal or delayed differentiation of mesodermal progenitor cells into the disorganized mass of blood vessels. In this paper, we discuss the literature that supports this emerging hypothesis.

Entities:  

Mesh:

Year:  2009        PMID: 19169153      PMCID: PMC2810465          DOI: 10.1097/SCS.0b013e318193d6ac

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  28 in total

Review 1.  Vascular anomalies.

Authors:  J B Mulliken; S J Fishman; P E Burrows
Journal:  Curr Probl Surg       Date:  2000-08       Impact factor: 1.909

2.  In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells.

Authors:  A Dosanjh; J Chang; S Bresnick; L Zhou; J Reinisch; M Longaker; M Karasek
Journal:  J Cutan Pathol       Date:  2000-10       Impact factor: 1.587

3.  Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.

Authors:  Jeffrey W Walter; Paula E North; Milton Waner; Adam Mizeracki; Francine Blei; John W T Walker; John F Reinisch; Douglas A Marchuk
Journal:  Genes Chromosomes Cancer       Date:  2002-03       Impact factor: 5.006

4.  Clonality and altered behavior of endothelial cells from hemangiomas.

Authors:  E Boye; Y Yu; G Paranya; J B Mulliken; B R Olsen; J Bischoff
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

5.  Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors.

Authors:  H Xu; J R Edwards; O Espinosa; S Banerji; D G Jackson; N A Athanasou
Journal:  Hum Pathol       Date:  2004-07       Impact factor: 3.466

6.  Infantile hemangiomas are arrested in an early developmental vascular differentiation state.

Authors:  Soheil S Dadras; Paula E North; Jennifer Bertoncini; Martin C Mihm; Michael Detmar
Journal:  Mod Pathol       Date:  2004-09       Impact factor: 7.842

7.  Endothelial progenitor cells in infantile hemangioma.

Authors:  Ying Yu; Alan F Flint; John B Mulliken; June K Wu; Joyce Bischoff
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

8.  In vitro characteristics of endothelium from hemangiomas and vascular malformations.

Authors:  J B Mulliken; B R Zetter; J Folkman
Journal:  Surgery       Date:  1982-08       Impact factor: 3.982

9.  Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology.

Authors:  Van Anh Nguyen; Christina Fürhapter; Nikolaus Romani; Florian Weber; Norbert Sepp
Journal:  Hum Pathol       Date:  2004-06       Impact factor: 3.466

10.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

View more
  9 in total

Review 1.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

2.  Hypothesis: the metastatic niche theory can elucidate infantile hemangioma development.

Authors:  Martin C Mihm; J Stuart Nelson
Journal:  J Cutan Pathol       Date:  2010-04       Impact factor: 1.587

Review 3.  Common Pediatric Skin Lesions: A Comprehensive Review of the Current Literature.

Authors:  Faryan Jalalabadi; Jeffrey G Trost; Joshua A Cox; Edward I Lee; Crystal Y Pourciau
Journal:  Semin Plast Surg       Date:  2016-08       Impact factor: 2.314

4.  Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells.

Authors:  Harun Elmasri; Cagatay Karaaslan; Yaroslav Teper; Elisa Ghelfi; Meiqian Weng; Tan A Ince; Harry Kozakewich; Joyce Bischoff; Sule Cataltepe
Journal:  FASEB J       Date:  2009-07-22       Impact factor: 5.191

5.  Infantile hemangioma status by dynamic infrared thermography: A preliminary study.

Authors:  Shoná A Burkes; Manish Patel; Denise M Adams; Adrienne M Hammill; Kenneth P Eaton; R Randall Wickett; Marty O Visscher
Journal:  Int J Dermatol       Date:  2016-04-08       Impact factor: 2.736

Review 6.  Complex vascular anomalies.

Authors:  Richard G Azizkhan
Journal:  Pediatr Surg Int       Date:  2013-10       Impact factor: 1.827

7.  Infantile Hemangioma Originates From A Dysregulated But Not Fully Transformed Multipotent Stem Cell.

Authors:  Shaghayegh Harbi; Rong Wang; Michael Gregory; Nicole Hanson; Keith Kobylarz; Kamilah Ryan; Yan Deng; Peter Lopez; Luis Chiriboga; Paolo Mignatti
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

Review 8.  Endothelial Ca2+ Signaling and the Resistance to Anticancer Treatments: Partners in Crime.

Authors:  Francesco Moccia
Journal:  Int J Mol Sci       Date:  2018-01-11       Impact factor: 5.923

9.  NOGOB receptor-mediated RAS signaling pathway is a target for suppressing proliferating hemangioma.

Authors:  Wenquan Hu; Zhong Liu; Valerie Salato; Paula E North; Joyce Bischoff; Suresh N Kumar; Zhi Fang; Sujith Rajan; M Mahmood Hussain; Qing R Miao
Journal:  JCI Insight       Date:  2021-02-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.